Tratamiento de las heridas antisepticos cambiando ideas

33. Upton A, Lang S, Heffernan H. Mupirocin and
Staphylococcus aureus: a recent paradigm of
emerging antibiotic resistance.
J Antimicrob.Chemother. 2003;51:613-7.
34. Walker ES, Vasquez JE, Dula R, Bullock H,
Sarubbi FA. Mupirocin-resistant, methicillinresistant
Staphylococcus aureus: does
mupirocin remain effective Infect.Control
Hosp.Epidemiol. 2003;24:342-6.
35. Georges B, Brown L, Mazerolles M., Decun
JF, Cougot P, Archambaud M et al. Infections
sévères à Staphylococcus aureus méticillinorésistants:
Emergence de résistance à
l’acide fusidique ou à la fosfomycine lors du
traitement par vancomycine en perfusion
continue. La Presse Médicale 1997;26:502-6.
36. O’Brien FG, Botterill CI, Endersby TG, Lim
RL, Grubb WB, Gustafson JE. Heterogeneous
expression of fusidic acid resistance in
Staphylococcus aureus with plasmid
or chromosomally encoded fusidic acid
resistance genes.
Pathology (Phila). 1998;30:299-303.
37. Miller YW, Eady EA, Lacey RW, Cove JH,
Joanes DN, Cunliffe WJ. Sequential antibiotic
therapy for acne promotes the carriage
of resistant staphylococci on the skin of
contacts.
J.Antimicrob.Chemother. 1996;38:829-37.
38. Mason BW,.Howard AJ. Fusidic acid
resistance in community isolates of
methicillin susceptible Staphylococcus
aureus and the use of topical fusidic acid: a
retrospective case-control study.
Int.J Antimicrob.Agents 2004;23:300-3.
39. Witte W, Cuny C, Strommenger B, Braulke
C, Heuck D. Emergence of a new community
acquired MRSA strain in Germany.
Euro.Surveill 2004;9:16-8.
40. Kesah C, Ben Redjeb S, Odugbemi TO,
Boye CS, Dosso M, Ndinya Achola JO et
al. Prevalence of methicillin-resistant
Staphylococcus aureus in eight African
hospitals and Malta.
Clin Microbiol.Infect. 2003;9:153-6.
41. Mason BW, Howard AJ, Magee JT. Fusidic
acid resistance in community isolates of
methicillin-susceptible Staphylococcus
aureus and fusidic acid prescribing.
J Antimicrob.Chemother. 2003;51:1033-6.
42. Shah M,.Mohanraj M. High levels of fusidic
acid-resistant Staphylococcus aureus in
dermatology patients.
Br.J Dermatol. 2003;148:1018-20.
43. Tveten Y, Jenkins A, Kristiansen BE. A fusidic
acid-resistant clone of Staphylococcus
aureus associated with impetigo bullosa is
spreading in Norway.
J Antimicrob.Chemother. 2002;50:873-6.
44. Manson JM, Keis S, Smith JM, Cook
GM. Acquired bacitracin resistance in
Enterococcus faecalis is mediated by an
ABC transporter and a novel regulatory
protein, BcrR. Antimicrob.Agents Chemother.
2004;48:3743-8.
45. Malhotra-Kumar S, Wang S, Lammens C,
Chapelle S, Goossens H. Bacitracin-resistant
clone of Streptococcus pyogenes isolated
from pharyngitis patients in Belgium.
J Clin Microbiol. 2003;41:5282-4.
46. McManus AT, Denton CL, Mason AD, Jr.
Mechanisms of in vitro sensitivity to
sulfadiazine silver.
Arch.Surg. 1983;118:161-6.
47. Bridges K,.Lowbury EJ. Drug resistance in
relation to use of silver sulphadiazine cream
in a burns unit. J.Clin.Pathol. 1977;30:160-4.
48. Pirnay JP, De Vos D, Cochez C, Bilocq F,
Pirson J, Struelens M et al. Molecular
epidemiology of Pseudomonas aeruginosa
colonization in a burn unit: persistence of
a multidrug-resistant clone and a silver
sulfadiazine-resistant clone.
J Clin Microbiol. 2003;41:1192-202.
49. Zaki I, Shall L, Dalziel KL. Bacitracin: a
significant sensitizer in leg ulcer patients
Contact Dermatitis 1994;31:92-4.
Bibliografía
69